AIM ImmunoTech Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AIM NYSE American 2830 aimimmuno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AIM ImmunoTech Inc.

AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies - Jul 2nd, 2025 6:55 am
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements - Jun 20th, 2025 2:15 pm
AIM ImmunoTech Resumes Trading on NYSE American - Jun 17th, 2025 6:55 am
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen® - Jun 12th, 2025 6:30 am
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension - Jun 12th, 2025 6:00 am
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - Apr 7th, 2025 11:26 am
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - Apr 4th, 2025 2:45 pm
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - Mar 27th, 2025 6:05 am
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Mar 11th, 2025 6:45 am
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza - Feb 28th, 2025 6:45 am
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - Feb 26th, 2025 11:20 am
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - Feb 26th, 2025 6:30 am
AIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer - Feb 25th, 2025 6:30 am
AIM ImmunoTech Releases Virtual Investor “What This Means Segment” - Feb 11th, 2025 6:45 am
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - Feb 11th, 2025 6:30 am
AIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM’s Ampligen® and AstraZeneca’s FluMist® to address the recent avian influenza outbreaks - Feb 7th, 2025 6:50 am
Erasmus Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic Cancer - Feb 5th, 2025 6:00 am
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions - Jan 23rd, 2025 6:50 am
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS - Jan 22nd, 2025 6:30 am
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - Jan 17th, 2025 10:00 am